EU Crunch Time For Diurnal’s Potentially 'Transformational' Rare Disease Drug
Executive Summary
The European Medicines Agency is deciding on the EU marketing application for Chronocort, a life-long treatment for congenital adrenal hyperplasia.
You may also be interested in...
Pivotal Moment In EU For Potential New Drugs
Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.
Pivotal Moment In EU For Potential New Drugs
Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.
Regulators Decide On EU Marketing For 'Game-Changing' Contraceptive
Mithra’s combined oral contraceptive Estelle includes estetrol, the first compound in the contraceptive area to be designated a new active substance in Europe in over 80 years.